Dr. Crombie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02115Phone+1 617-632-3000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2015 - 2018- Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
University of Massachusetts Medical SchoolClass of 2012
Certifications & Licensure
MA State Medical License 2014 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Copanlisib Plus Venetoclax in R/R DLBCL Start of enrollment: 2021 Sep 08
- Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL Start of enrollment: 2021 Feb 18
- Safe Accelerated Venetoclax Escalation in CLL Start of enrollment: 2021 Apr 14
Roles: Contact, Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- A Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in a Treatment-Naive CLL Population Enriched for High-Risk Disease.Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2024-12-07 - A real-world comparison of commercial use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma.Andrew Looka, David A Qualls, Daniel Matthews, Robert A Redd, Christopher Sakellis
Blood Advances. 2024-11-15 - Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers.Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, Kaitlin Annunzio, Aditi Saha
Haematologica. 2024-11-14
Journal Articles
- Current Considerations in AYA Hodgkin LymphomaJennifer L Crombie, Ann S LaCasce, British Journal of Haematology
Abstracts/Posters
- Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...Jennifer L. Crombie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...Jennifer L. Crombie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid MalignanciesAugust 24th, 2021
Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with VenetoclaxDecember 10th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
